SCHEMBL23219102

SCHEMBL23219102

Cc1oc2c(cc(Br)c3occc32)c1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.40
KMT2A Q03164 7/20 0.40
KEAP1 Q14145 2/20 0.40
NFE2L2 Q16236 2/20 0.40
GAA P10253 2/20 0.40
POLB P06746 2/20 0.39
MAPT P10636 4/20 0.38
CASP6 P55212 2/20 0.38
ACLY P53396 1/20 0.38
SLC26A4 O43511 2/20 0.38
BLM P54132 1/20 0.38
ATM Q13315 1/20 0.38
CYP2C19 P33261 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 2/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591158 1.00 MEN1 (0.40) MEN1KMT2AKEAP1NFE2L2GAA
SCHEMBL23219016 0.83 MAPT (0.57) MEN1KMT2AGAAMAPTCYP2C19
SCHEMBL29591076 0.83 MAPT (0.57) MEN1KMT2AGAAMAPTCYP2C19
SCHEMBL29591463 0.79 POLB (0.40) MEN1KMT2AKEAP1NFE2L2GAA
SCHEMBL23218735 0.79 POLB (0.40) MEN1KMT2AKEAP1NFE2L2GAA
SCHEMBL23219021 0.75 HTR2A (0.35) CYP3A4ALDH1A1
SCHEMBL29591281 0.75 HTR2A (0.35) CYP3A4ALDH1A1
SCHEMBL29591484 0.74 HTR2A (0.36) CYP3A4ALDH1A1
SCHEMBL23218782 0.74 HTR2A (0.36) CYP3A4ALDH1A1
SCHEMBL19683573 0.68 HTR2A (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MEN1 1819/4885KMT2A 4445/4885KEAP1 1521/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MEN1 548/4885KMT2A 4835/4885KEAP1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.